(WENY) - Regeneron Pharmaceuticals coronavirus treatment cuts the risk of death significantly, according to researchers. Studies find the monoclonal antibody cocktail reduces the risk of both death and hospitalization in high-risk patients by 70%.

In addition, the drug, called Regen-COV cut down the average recovery time from 14 days to 10. Researchers looked at more than 4,000 patients. The drug is given through an IV. Regeneron Pharmaceuticals is testing it in shot form to make it easier to use.

The results have not been published or reviewed by independent scientists as of right now. Regen-COV is still in its trial phases.